Description
CJC – 1295 no DAC Ipamorelin | 10MG
BioChain USA · Research use only
⚠
For research use only. Not for human or animal consumption. This compound is sold exclusively for in vitro research, laboratory, and analytical purposes by BioChain USA. It is not a drug, supplement, or therapeutic product of any kind.
What Is the CJC-1295 (No DAC) + Ipamorelin Research Blend?
This product contains two distinct synthetic peptides combined in a single lyophilized preparation: CJC-1295 (No DAC) (Modified GRF(1-29), 5 mg) and Ipamorelin (NNC 26-0161, 5 mg). Each compound stimulates growth hormone (GH) release from pituitary somatotroph cells through a distinct receptor pathway.
This blend is used in research contexts to study the combined effects of activating both the GHRH receptor and the ghrelin receptor simultaneously in experimental models.
CJC-1295 (No DAC) (also referenced in the literature as Modified GRF(1-29) or Mod GRF 1-29) is a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH). It incorporates amino acid substitutions relative to endogenous GHRH(1-29) to improve enzymatic stability in experimental systems.
It acts as an agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells. The “No DAC” designation indicates the absence of a Drug Affinity Complex modification, distinguishing it from longer-acting CJC-1295 formulations in research literature.
Ipamorelin (also referenced as NNC 26-0161) is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts as a selective agonist at the ghrelin receptor (GHS-R1a).
It is studied in published literature for its selective stimulation of GH release without significant effects on cortisol or prolactin secretion, a selectivity profile that distinguishes it from earlier GHS compounds in the research literature.
CJC-1295 (no DAC) + Ipamorelin in Plain Language
A non-technical overview of what this two-peptide blend is, what researchers have studied each component for, what early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.
Research-Use Disclaimer. BioChain USA sells this blend strictly as a research-use-only chemical preparation. It is not a drug, dietary supplement, or medical product. Neither CJC-1295 (no DAC) nor ipamorelin is approved by the FDA or any other major regulator for any use.
It is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of any condition. No statements on this page have been evaluated by the FDA.
At a glance
CJC-1295 and ipamorelin are two lab-made peptides researchers commonly study together. They each work on a different part of the body’s natural growth-hormone system, one nudges the signal that triggers growth-hormone release, the other amplifies it, and together they appear to produce a more natural, pulsed pattern of release in laboratory studies.
Scientists are interested in what this combination can teach us about growth-hormone biology, body composition, recovery after injury or surgery, and age-related changes. The compounds sold here are research chemicals, not pharmaceuticals, and are not for human or animal use.
What it is
This product is a combined research preparation of two peptides that act on related but distinct receptor systems involved in growth hormone (GH) release:
- CJC-1295 (no DAC). A 30-amino-acid analog of growth hormone-releasing hormone (GHRH), also known in the literature as Modified GRF (1-29) or Mod GRF 1-29. The “no DAC” form lacks the Drug Affinity Complex (a maleimido group used to covalently bind serum albumin in the long-acting CJC-1295 with DAC variant), so its functional half-life is short, on the order of about 30 minutes, rather than days. Engineered amino acid substitutions at positions 2, 8, 15, and 27 are described in published research as protecting the molecule from enzymatic breakdown.
- Ipamorelin. A synthetic five-amino-acid peptide (Aib-His-D-2Nal-D-Phe-Lys-NH₂) that is a growth hormone secretagogue: it activates the GHS receptor (GHSR-1a, also called the ghrelin receptor). Published pharmacology describes ipamorelin as having unusually high selectivity for GHSR-1a, with minimal off-target effects on cortisol, prolactin, ACTH, or aldosterone in research models, a profile that distinguishes it from non-selective growth hormone secretagogues.
Researchers commonly study these two peptides together because they engage two different upstream pathways that converge on the same downstream output (pulsatile GH release from the pituitary): GHRH-receptor agonism and GHSR-1a agonism.
Research areas being investigated
- GHRH-receptor pharmacology research: CJC-1295 (no DAC) is studied as a stabilized GHRH analog probe of the GHRH receptor and downstream cAMP / PKA signaling.
- GHSR-1a / ghrelin-receptor research: Ipamorelin is studied as a selective GHSR-1a agonist for receptor pharmacology and signaling.
- Pulsatile GH release research: Combined pathway activation is studied for its effects on the timing and amplitude of GH pulses in pituitary research models.
- IGF-1 axis research: Downstream IGF-1 production by hepatocytes following GH-axis activation.
- Off-target hormone profile research: Ipamorelin is studied as a comparator to non-selective growth hormone secretagogues.
- Peptide-engineering research: CJC-1295 is studied in literature on N-terminal modification and structure-activity relationships in GHRH analogs.
What the research suggests so far
Animal / preclinical findings. Animal studies on CJC-1295 (with and without DAC) report dose-dependent increases in serum GH and IGF-1, as expected for a GHRH-receptor agonist. Animal studies on ipamorelin describe selective GH release with minimal disturbance of cortisol, prolactin, and ACTH at doses that produce robust GH responses, a feature published research uses to distinguish ipamorelin from non-selective GHSs.
Combined administration of GHRH analogs and GHS receptor agonists has been described in published pituitary-physiology research as producing a synergistic GH pulse relative to either pathway alone.
Cell / lab findings. Cell-culture pharmacology has characterized CJC-1295 binding to GHRHR with cAMP / PKA signaling, and ipamorelin binding to GHSR-1a with Gαq / PLC / IP3 signaling. Comparative pharmacology has documented ipamorelin’s receptor selectivity over related receptors expressed in pituitary somatotrophs and other neuroendocrine cells.
Human findings. Human evidence for both molecules is limited. Early-phase human pharmacology studies have examined the long-acting CJC-1295 with DAC variant, with reports on GH and IGF-1 dynamics in healthy volunteers. Ipamorelin entered Phase II clinical investigation by Helsinn / Novo Nordisk for postoperative ileus in the 2000s, but the program did not proceed to regulatory approval.
There are no large, published Phase III randomized controlled trials demonstrating efficacy for any condition. Neither CJC-1295 (no DAC) nor ipamorelin is approved by the FDA, EMA, or other major regulators for any use.
Limitations of the evidence. Human evidence is limited to early-phase studies and does not establish long-term safety or efficacy. Public-health agencies including the FDA have specifically warned about non-pharmaceutical compounded or research-grade growth-hormone-secretagogue and GHRH-analog products. Research-grade material is not equivalent to a finished pharmaceutical product in formulation, sterility, dosing accuracy, or oversight.
Research relevance
This blend is most often discussed in research involving GHRH-receptor and GHSR-1a (ghrelin-receptor) pharmacology, pulsatile GH release from pituitary somatotrophs, downstream IGF-1 biology, and the comparative pharmacology of selective vs. non-selective growth hormone secretagogues. Most published findings are preclinical or early-phase, so it should not be presented as a proven treatment for any condition.
What cannot be claimed about CJC-1295 / ipamorelin
- It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
- It cannot be claimed to be FDA-approved or to be equivalent to any approved drug.
- It cannot be claimed to treat growth hormone deficiency, age-related decline in GH, sarcopenia, or short stature.
- It cannot be claimed to build muscle, burn fat, improve athletic performance, slow aging, or improve sleep quality in customers.
- It cannot be claimed to be safe or effective for human or veterinary use.
- It cannot be represented as a dietary supplement.
Summary
This research preparation combines two peptides that engage different upstream pathways converging on pituitary growth hormone release: CJC-1295 (no DAC), a stabilized 30-amino-acid GHRH analog with a short functional half-life (about 30 minutes), and ipamorelin, a selective five-amino-acid GHSR-1a (ghrelin-receptor) agonist with minimal effects on cortisol, prolactin, and ACTH. They are studied in laboratory and animal research on GHRH-receptor and GHSR-1a pharmacology, pulsatile GH release, IGF-1 biology, and selective vs. non-selective growth hormone secretagogue research.
Neither molecule is approved by the FDA or any other regulatory authority. BioChain USA’s preparation is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.
Short version
This blend combines a stabilized GHRH analog (CJC-1295 no DAC, also called Mod GRF 1-29) with a selective ghrelin-receptor agonist (ipamorelin). They are studied in preclinical research on growth-hormone release. Neither is approved by the FDA. Sold for research and laboratory use only.
Source notes
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006, small early-phase human study (CJC-1295 with DAC).
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab, 2006, small early-phase human study.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998, foundational pharmacology / discovery report.
- Beck DE, et al. A randomized, multicenter, controlled trial of pharmacological postoperative ileus management with ipamorelin. Helsinn / Novo Nordisk Phase II clinical trial program, investigational pharmaceutical research that did not proceed to regulatory approval.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev, 2018, review article on growth-hormone secretagogues including CJC-1295 and ipamorelin.
Source types: entries 1, 2 are small early-phase human studies of CJC-1295 with DAC (a related but distinct molecule from CJC-1295 no DAC); entry 3 is a foundational pharmacology study; entry 4 references investigational pharmaceutical research that did not proceed to approval; entry 5 is a review article.
SEO meta description
CJC-1295 (no DAC) + ipamorelin (research-grade) is a blend of a GHRH analog and a selective ghrelin-receptor agonist studied in preclinical research on GH release. Research-use only.
Reminder. BioChain USA sells this blend strictly as a research-use-only chemical for qualified laboratory and educational use. Neither CJC-1295 (no DAC) nor ipamorelin is FDA-approved, and this product is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.
Chemical Reference Data
CJC-1295 (No DAC), Modified GRF(1-29)
| Molecular Formula | C152H252N44O42 |
|---|---|
| Molecular Weight | ~3,367.9 g/mol |
| Peptide Length | 29 amino acids |
| Structural Classification | Synthetic modified analogue of GHRH(1-29) with stabilizing amino acid substitutions |
| CAS Number | 863288-34-0 |
Ipamorelin (NNC 26-0161)
| Molecular Formula | C38H49N9O5 |
|---|---|
| Molecular Weight | ~711.9 g/mol |
| Peptide Length | 5 amino acids (pentapeptide) |
| Structural Classification | Synthetic pentapeptide GHS containing non-natural amino acid residues (Aib, D-2-Naphthylalanine, D-Phe) |
| CAS Number | 170851-70-4 |
Structural Design and Engineering
CJC-1295 (No DAC) is a modified version of the first 29 amino acids of endogenous human GHRH, the minimum sequence required for GHRHR binding and activation. Published literature describes the “Modified GRF(1-29)” designation as reflecting four amino acid substitutions relative to native GHRH(1-29), engineered to reduce susceptibility to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV) and other proteases in biological systems.
These substitutions are discussed in research as increasing the functional persistence of the peptide in experimental assays without altering the core GHRHR agonist activity. The absence of a Drug Affinity Complex (DAC) means this variant does not incorporate an albumin-binding modification, producing a shorter exposure profile relative to DAC-containing CJC-1295 formulations, a distinction commonly used in research design to model pulsatile versus sustained GH stimulation patterns.
Ipamorelin is a compact 5-amino acid synthetic peptide incorporating three non-natural amino acid residues: α-aminoisobutyric acid (Aib), D-2-naphthylalanine, and D-phenylalanine. Published research describes this non-natural residue composition as conferring resistance to enzymatic degradation and conferring receptor selectivity.
Ipamorelin is described in published pharmacology literature as a “third-generation” growth hormone secretagogue, characterized by its selective activation of GHS-R1a with minimal off-target activity at receptors associated with cortisol or prolactin release, a selectivity profile noted in multiple published comparison studies against earlier GHS compounds.
BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Research Applications
This peptide blend is used as a research tool to investigate:
- CJC-1295 (No DAC), GHRH receptor (GHRHR) agonism and downstream pituitary somatotroph signaling in experimental models
- CJC-1295 (No DAC), Pulsatile GH secretion modeling, short-acting GHRH analogue dynamics compared with sustained-release formulations in research designs
- CJC-1295 (No DAC), DPP-IV resistance, studying how amino acid substitutions affect enzymatic stability and functional persistence in biological systems
- Ipamorelin, Ghrelin receptor (GHS-R1a) agonism and selective GH secretagogue signaling in pituitary and hypothalamic research models
- Ipamorelin, GHS receptor selectivity profiling, examining differential effects on GH, cortisol, and prolactin secretion pathways
- Dual pathway GH secretagogue research, simultaneous GHRHR and GHS-R1a activation and the combined downstream effects on GH pulse dynamics
- Somatotropic axis research, hypothalamic-pituitary signaling cascade investigation in in vitro and preclinical model systems
- Synergistic secretagogue co-administration research, published literature describes GHRH-pathway and ghrelin-pathway co-activation as a common preclinical research design for studying amplified GH release responses
Specific applications depend on the researcher’s study design, cell model, and assay framework.
Key Research Themes in the Literature
1. CJC-1295 (No DAC): GHRH Receptor Signaling and Pulsatile GH Research
CJC-1295 (No DAC) / Modified GRF(1-29) is studied in the literature as a tool for investigating GHRH receptor-mediated signaling in pituitary somatotroph cells. GHRHR is a G protein-coupled receptor (GPCR); published research describes its activation as increasing intracellular cAMP, which drives GH synthesis and secretion from somatotroph cells.
A key research theme in the CJC-1295 (No DAC) literature is the distinction between pulsatile and sustained GH release patterns. Because the No DAC formulation lacks albumin-binding modification, it exhibits a shorter active window in experimental systems, a design property used by researchers to model discrete GH pulses, analogous to the endogenous pulsatile GH secretion pattern.
This makes it a frequently used tool in somatotropic axis research designs comparing pulsatile versus continuous GH stimulation.
2. Ipamorelin: Ghrelin Receptor Selectivity and GH Secretagogue Research
Ipamorelin is described in published pharmacology literature as a selective GHS-R1a agonist. Research themes include:
- GHS-R1a receptor binding and activation, mechanism of ghrelin receptor engagement and downstream signaling compared with endogenous ghrelin and earlier synthetic GHS compounds
- Selectivity profiling, published comparison studies have examined ipamorelin alongside earlier GHS compounds (GHRP-2, GHRP-6), with ipamorelin noted for a narrower activation profile that limits off-target effects on cortisol and prolactin secretion in preclinical models
- GH pulse amplitude research, how GHS-R1a agonism modulates the amplitude and duration of GH secretion events in pituitary cell models
3. Dual Pathway Activation: GHRHR + GHS-R1a Co-Stimulation
A prominent research theme in the GH secretagogue literature is the concept of synergistic GH release via simultaneous activation of both the GHRH receptor pathway and the ghrelin receptor pathway. Published research describes these two pathways as mechanistically distinct but functionally convergent at the level of pituitary somatotroph GH release:
- GHRHR activation elevates intracellular cAMP via Gs-coupled signaling
- GHS-R1a activation operates through a separate Gq-coupled signaling pathway involving IP3 and intracellular calcium mobilization
Co-administration of GHRH-pathway and ghrelin-pathway agonists is documented in preclinical and clinical research literature as producing GH release responses that exceed those of either compound alone, a theme frequently cited as the rationale for studying these two compound classes together in experimental designs.
4. Somatotropic Axis Research and Physiological Context
Both CJC-1295 (No DAC) and Ipamorelin appear in research literature examining the hypothalamic-pituitary somatotropic axis, the regulatory system governing GH synthesis, pulsatile secretion, and downstream IGF-1 production. Published research themes in this context include:
- Hypothalamic regulation of pituitary GH secretion via GHRH and somatostatin tone
- Feedback loop dynamics, how GH and IGF-1 modulate hypothalamic and pituitary signaling in model systems
- Age-related changes in somatotropic axis activity examined in preclinical model systems using GH secretagogue tools
BioChain USA does not represent these research themes as consumer outcomes or therapeutic claims. These are published research literature contexts only.
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
- COA information is batch-specific and is not interchangeable between lots. For blend products, COA documentation reflects testing of the combined preparation as shipped.
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- For extended storage, follow standard peptide handling protocols: cold storage with protection from light and moisture.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
- If preparing solutions for laboratory use, standard guidance recommends avoiding long-term storage in reconstituted form, aliquot as appropriate for the experimental design.
BioChain USA does not provide instructions for human or animal administration.
Frequently Asked Questions
Is this product for human use?
No. This peptide blend is not approved or intended for human or veterinary use. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What are CJC-1295 (No DAC) and Ipamorelin used for in research?
CJC-1295 (No DAC) is studied as a GHRH receptor agonist for investigating pituitary somatotroph signaling, pulsatile GH secretion dynamics, and DPP-IV-resistant peptide engineering in experimental models. Ipamorelin is studied as a selective ghrelin receptor (GHS-R1a) agonist for GH secretagogue signaling research, receptor selectivity profiling, and GH pulse amplitude investigation.
Together they are used in co-administration research designs examining dual-pathway GH secretagogue activation and somatotropic axis signaling. Specific applications depend on the researcher’s study design and objectives.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
In published research literature, the “DAC” (Drug Affinity Complex) designation refers to a lysine-maleimidopropionic acid modification that enables covalent albumin binding, significantly extending the compound’s persistence in biological systems. The “No DAC” formulation lacks this modification and exhibits a shorter active window in experimental models, a property used in research designs that model pulsatile, discrete GH release events rather than sustained stimulation.
These are research literature distinctions only. BioChain USA does not provide guidance on human use.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. Availability may vary by lot.
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.
References & additional CJC-1295 + Ipamorelin resources
CJC-1295 + Ipamorelin Overview at BioChain USA
This CJC-1295 + Ipamorelin product page lists the 10 mg lyophilized vial of the BioChain USA research-grade CJC-1295 + Ipamorelin compound.
Every CJC-1295 + Ipamorelin lot is independently third-party tested, with a COA available per batch.
CJC-1295 + Ipamorelin is supplied strictly for in vitro research use and is not approved for human or animal consumption.
CJC-1295 + Ipamorelin Product Imagery
Related BioChain Research Peptides
CJC-1295 + Ipamorelin is part of a broader catalog of research-grade peptides at BioChain USA. Each related product is third-party tested.
- Tesamorelin research-grade peptide
- Tirzepatide research-grade peptide
- GLP-RT3 research-grade peptide
- MOTS-c research-grade peptide
External Peer-Reviewed Research Literature
Investigators studying the CJC-1295 + Ipamorelin compound class may consult external research databases for published literature.
- PubMed: CJC-1295 + Ipamorelin published research literature
- NCBI PMC: CJC-1295 + Ipamorelin open access articles
- PubMed: peptide research literature
CJC-1295 + Ipamorelin FAQ
What is CJC-1295 + Ipamorelin? CJC-1295 + Ipamorelin is a research-grade compound supplied by BioChain USA as a lyophilized vial for in vitro laboratory research only.
What vial size does BioChain USA offer? This product page lists the 10 mg vial size.
Is CJC-1295 + Ipamorelin tested? Yes. Every CJC-1295 + Ipamorelin lot is independently third-party tested and ships with a COA reference when available.
Can CJC-1295 + Ipamorelin be used on humans or animals? No. CJC-1295 + Ipamorelin is supplied strictly for in vitro research use. It is not approved for human or animal consumption.
How does CJC-1295 + Ipamorelin ship? BioChain USA ships CJC-1295 + Ipamorelin as a lyophilized powder in a sealed research vial.
Where can researchers find CJC-1295 + Ipamorelin published literature? PubMed and NCBI PMC list peer-reviewed studies on the CJC-1295 + Ipamorelin compound class.
